Results from a clinical trial led by researchers from Queen Mary University of London, published today in JAMA , show that giving people with high blood pressure an injection every six months can lead to a meaningful, sustained reduction in their blood pressure.
The global trial, KARDIA-2, involved 663 people with high blood pressure whose condition wasn’t being well managed with their standard treatment.
In the trial, patients were given an injection of a new medication zilebesiran, alongside their standard blood pressure treatments. Researchers found that giving patients zilebesiran alongside their standard medication was better at reducing their blood pressure levels than standard medication alone.
The results could have a big positive impact for those with high-blood pressure, which affects around 1 in 3 adults in the UK and, if left untreated, increases the risk of cardiovascular events such as heart attacks, strokes and even death.
Dr Manish Saxena, Clinical Co-Director of the William Harvey Clinical Research Centre at Queen Mary University of London and a hypertension specialist at Barts Health NHS Trust was the lead investigator for the study in the UK and senior author on the new publication. Speaking on the results, he said:
"Hypertension is a global health concern as blood pressure control rates remain poor and is a leading cause of heart attacks and strokes. This study demonstrates the efficacy and safety of zilebesiran , when added to commonly used first line blood pressure lowering drugs. The novelty of this treatment is its long duration; giving just one injection every six months could help millions of patients to better manage their condition.”
Zilebesiran is an investigational therapeutic that uses RNA interference technology. It blocks the production of a specific protein in the liver (angiotensinogen), helping blood vessels to relax and lowering blood pressure. The injection is given under the skin.
The next steps for zilebesiran involve another Phase 2 study, KARDIA-3, to see if this treatment has potential to be used to treat people with high blood pressure and established cardiovascular disease, or those at high risk of cardiovascular disease.
Later this year, the sponsor plans to enrol patients in a big global outcomes study to understand its effect on reducing cardiovascular events, strokes and cardiovascular death.
The study was funded by Alnylam Pharmaceuticals, with Barts Health NHS Trust serving as a lead site for the trial and top European enroller on the study.
ENDS
NOTES TO EDITORS
Contact
Press office
Queen Mary University of London
Paper details:
Manesh Saxena, et al . “Zilebesiran as Add-On Therapy in Patients with Hypertension Inadequately Controlled with a Standard Antihypertensive Medication: Efficacy and Safety Results from the KARDIA-2 Study.” Published in JAMA .
DOI: doi:10.1001/jama.2025.6681
Available after publication at: https://jamanetwork.com/journals/jama/article-abstract/2834632
Funded by: Alnylam Pharmaceuticals.
About Queen Mary
At Queen Mary University of London, we believe that a diversity of ideas helps us achieve the previously unthinkable.
Throughout our history, we’ve fostered social justice and improved lives through academic excellence. And we continue to live and breathe this spirit today, not because it’s simply ‘the right thing to do’ but for what it helps us achieve and the intellectual brilliance it delivers.
Our reformer heritage informs our conviction that great ideas can and should come from anywhere. It’s an approach that has brought results across the globe, from the communities of east London to the favelas of Rio de Janeiro.
We continue to embrace diversity of thought and opinion in everything we do, in the belief that when views collide, disciplines interact, and perspectives intersect, truly original thought takes form.
JAMA
Randomized controlled/clinical trial
People
Zilebesiran as Add-On Therapy in Patients with Hypertension Inadequately Controlled with a Standard Antihypertensive Medication: Efficacy and Safety Results from the KARDIA-2 Study
28-May-2025